Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. - Wikidata - awgldk - TriplyDB

Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.

Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.

http://www.wikidata.org/entity/Q34118958

about

Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis Current concepts in the management of rheumatoid arthritis Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Impact of methotrexate dose on efficacy of adalimumab in Japanese patients with rheumatoid arthritis: Results from registered data analyses.Anti-citrullinated peptide antibodies are the strongest predictor of clinically relevant radiographic progression in rheumatoid arthritis patients achieving remission or low disease activity: A post hoc analysis of a nationwide cohort in Japan.Adalimumab with Methotrexate in Treatment-Naïve Japanese Patients with Rheumatoid Arthritis at Risk of Progressive Structural Joint Damage: A Postmarketing Observational Study Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies.Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis.Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA).Continuously elevated serum matrix metalloproteinase-3 for 3 ~ 6 months predict one-year radiographic progression in rheumatoid arthritis: a prospective cohort study.Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study.MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy.Prognostic Factors Toward Clinically Relevant Radiographic Progression in Patients With Rheumatoid Arthritis in Clinical Practice: A Japanese Multicenter, Prospective Longitudinal Cohort Study for Achieving a Treat-to-Target Strategy Long-term treatment of rheumatoid arthritis with adalimumab.Non-pharmacological and pharmacological interventions in patients with early arthritis: a systematic literature review informing the 2016 update of EULAR recommendations for the management of early arthritis.Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis.Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study.Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study.Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial.Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers.Pleiotrophin, the angiogenic and mitogenic growth factor: levels in serum and synovial fluid in rheumatoid arthritis and osteoarthritis : And correlation with clinical, laboratory and radiological indices.An effective medical partnership in Nagasaki, Japan for patients with rheumatoid arthritis.Time lag between the initiation of adalimumab after methotrexate correlates with the efficacy of adalimumab in rheumatoid arthritis patients.Long-term safety and effectiveness of adalimumab for the treatment of Japanese patients with rheumatoid arthritis: 3-year results from a postmarketing surveillance of 552 patients.Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study.Origins of fibroblasts in rheumatoid synovial tissues: Implications from organ fibrotic models.Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis.Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study.Presence of hepatitis B virus in synovium and its clinical significance in rheumatoid arthritis.

P2860

Q24185797-CB8015AD-4AE6-42D8-9670-1FF69B9DA4E8 Q26765124-DB3EC6E4-70E8-43A5-83A9-025FC31E03DA Q30234528-F82C2C29-88E6-451D-99EA-ADCB8FCA2BDC Q30235341-1658BA2B-36EC-4612-A690-B8FCAC0101AF Q30240183-6E6663CF-F79D-42E9-A282-4FBBEF5BE9BC Q30240212-6809F7A8-AB98-4ADE-8280-2CC5E28FBE02 Q31090015-1062C769-A76C-4BAC-A3D0-439B497512F7 Q33688001-396F7AF0-AA40-4444-9516-A374ED68C317 Q33725547-4D1CB1EF-A15D-441B-9EE0-B8C3F4D1B293 Q34067792-C0E2578E-D98E-404D-AD8E-F575D12CA473 Q34468474-5C5BEA2C-343E-4268-B1FA-E53FA3F629F7 Q35605449-F65A1996-942F-4E0E-AD19-113389F1E2D1 Q35914971-12704D34-294A-4B4A-9157-84A36F6E7A04 Q36164886-E7B35BA0-6F6E-4C35-BDED-7847E3C876AB Q36195284-415FDA26-E1CF-48B0-A508-F0441431E14F Q36475622-6669C3FC-8A0F-470E-A708-2D5F199F5A77 Q36603276-D6A56FF2-E56D-4C0B-ABD0-2B3E80E9221E Q36625596-318A96C7-7661-40EB-92B2-74A1287C0385 Q37206416-C0252E59-5466-4ECD-B55F-4DE37C068EC3 Q37358278-C97736F1-205C-4627-9B30-5D4C3096548F Q37587409-883327CD-F5FB-4487-84E5-94289238538F Q37587412-4E036F37-4B7E-41E4-8A07-61430296BCDC Q37697988-F3CD0491-12D1-4442-BF8E-69397D9A0D02 Q37699707-5FBE18AC-8A3A-4DE9-825C-96222293103A Q37706297-8C9FC803-BA82-4EE6-970D-41F522BD950E Q38939820-E3303E69-C3FF-477D-B4D8-59702930C7BE Q38991972-DCAC4DDC-2B2A-427B-BEFD-4B0F9A1B14A5 Q39140572-896973FF-941F-4AE6-A9D9-6FE3FD51A08A Q39967995-FD34E65C-7A60-4EDD-8435-CBCE12CF0D30 Q40166955-F4F3213C-1BFB-4FC3-8F1B-3AF1114EAE1E Q40253228-595CFA57-D1DD-4382-9E95-705230F41AED Q40353155-9DECB5AD-C8DB-4B59-A374-41389E136512 Q47276595-9FAE97C5-A2D7-4C16-9914-E07E1EC19904 Q48744497-F4CB0C89-2583-4BFC-AF89-32767CE951AD Q50079696-AA7DFAB0-70CE-48FB-A9DD-8824AABDC7E4 Q50918813-C88A38F0-4A40-40D6-B492-EDCB83F7FC97 Q54222708-CA3D3D58-1784-4F78-BA4B-A2E1A8CC6A20 Q55379977-24815F95-515B-4343-91F4-3BE70D847331

P2860

Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.

http://www.wikidata.org/entity/Q34118958

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Adalimumab, a human anti-TNF m ...... rthritis: the HOPEFUL 1 study.

@ast

Adalimumab, a human anti-TNF m ...... rthritis: the HOPEFUL 1 study.

@en

Adalimumab, a human anti-TNF m ...... rthritis: the HOPEFUL 1 study.

@nl

type

label

Adalimumab, a human anti-TNF m ...... rthritis: the HOPEFUL 1 study.

@ast

Adalimumab, a human anti-TNF m ...... rthritis: the HOPEFUL 1 study.

@en

Adalimumab, a human anti-TNF m ...... rthritis: the HOPEFUL 1 study.

@nl

prefLabel

Adalimumab, a human anti-TNF m ...... rthritis: the HOPEFUL 1 study.

@ast

Adalimumab, a human anti-TNF m ...... rthritis: the HOPEFUL 1 study.

@en

Adalimumab, a human anti-TNF m ...... rthritis: the HOPEFUL 1 study.

@nl

P1433

Q34118958-D58DC0D3-430C-491C-85F4-A819279D1281

P1476

Q34118958-3D77DF9C-2782-4176-B254-84358DE11431

P2093

Q34118958-06A0C7D3-A65D-49F7-A80B-D8AEAC07E527

Q34118958-214B7152-1101-4F4B-9503-58777ED3ED87

Q34118958-240E1B63-8D6E-411D-8A69-0C4BD858B0B9

Q34118958-ADE5DDC0-F33C-43E5-85E8-00F9D8887307

Q34118958-B4352411-F32C-44F2-B8D3-2948A8ECD3FD

Q34118958-CDC85262-F74A-4503-9059-E33A3F33A674

Q34118958-E002E4F2-259B-42CA-B57D-A91A792DC92A

Q34118958-E0742F9F-2812-4420-920E-6C8A6D826B19

Q34118958-E686A5D5-5A3C-4BB3-8263-1AE3CACA8DFB

Q34118958-F924A4BB-1206-4A5A-AA2F-1811BD1ECC07

P2860

Q34118958-14FA353E-E298-436A-AD40-C1B022D21F23

Q34118958-2A8CCA40-6F48-4A02-AD3D-76F129FA1F0B

Q34118958-2BB526A8-BD9B-4A8D-9B6A-4982B36B8C19

Q34118958-3D7DA473-1B0A-47F7-A558-F7D380D5A734

Q34118958-48F3AA33-3112-4B48-BE99-41D3B88AF093

Q34118958-4CDC280C-3B88-48D9-B5DC-D221F9DC3E93

Q34118958-619335A0-621E-4589-ADB2-BF75C99EF276

Q34118958-83E9E0DB-FB58-48D3-B9C7-1771AFA87115

Q34118958-8FD62E58-E58D-44F5-AA18-4A9E9E4F7C80

Q34118958-A90C9267-A32A-4084-BAD3-394E5F64CA66

P304

Q34118958-FA07FEA9-0F7B-4A3E-A283-5581B03632C9

P31

Q34118958-9D891012-9AC4-45F8-BA1D-076604176291

P356

Q34118958-1AF2A459-D677-443D-845F-695B303C4FD4

P407

Q34118958-DF61474F-E643-419C-A5A4-6CFE0277678D

P433

Q34118958-F0FE8591-CD5C-4ACB-B1B7-F9A7FD560246

P478

Q34118958-EE2A381F-6893-4A56-9D4E-F5CDFEF62395

P50

Q34118958-8822C5B9-C64C-4811-A548-68A22FB3DB8B

P577

Q34118958-2CF1A966-F6D6-423A-9225-571413FA5DEE

P5875

Q34118958-D119E219-7968-4F62-950F-EB54AFFAB1F5

P698

Q34118958-A5ADEC11-F22C-4517-AEB0-8BD688E6BAF2

P921

Q34118958-3C7CC2C8-590F-4B76-9AC6-6E17602966A7

Q34118958-3D506272-1EA6-4ABE-BDE1-49061ED25975

Q34118958-6FA9ABA6-E985-4C07-9D96-5FD75AEF904B

Q34118958-721204E5-B0DB-45CF-8357-7FB62C2FA15E

Q34118958-BEA0388D-E13D-4436-86C8-EB9BB8AA5C92

P932

Q34118958-5E04BC3C-94C2-47EB-940E-A89EFD1B4E2A

P356

ANNRHEUMDIS-2012-202433

P1433

Annals of the Rheumatic Diseases

P1476

Adalimumab, a human anti-TNF m ...... rthritis: the HOPEFUL 1 study.

@en

P2093

Hartmut Kupper

http://www.w3.org/2001/XMLSchema#string

Hideto Akama

http://www.w3.org/2001/XMLSchema#string

Hisashi Yamanaka

http://www.w3.org/2001/XMLSchema#string

Masaya Mukai

http://www.w3.org/2001/XMLSchema#string

Naoki Ishiguro

http://www.w3.org/2001/XMLSchema#string

Nobuyuki Miyasaka

http://www.w3.org/2001/XMLSchema#string

Shoji Uchida

http://www.w3.org/2001/XMLSchema#string

Tsukasa Matsubara

http://www.w3.org/2001/XMLSchema#string

Vipin Arora

http://www.w3.org/2001/XMLSchema#string

Yoshiya Tanaka

http://www.w3.org/2001/XMLSchema#string

P2860

Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis.

Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study).

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Treating rheumatoid arthritis to target: recommendations of an international task force.

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

P304

536-543

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ANNRHEUMDIS-2012-202433

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P50

Tsutomu Takeuchi

P577

2013-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234124933

http://www.w3.org/2001/XMLSchema#string

P698

23316080

http://www.w3.org/2001/XMLSchema#string

P921

P932

4151516

http://www.w3.org/2001/XMLSchema#string